Under the deal, Opocrin will concurrently make an investment in Dilafor and be appointed as the main commercial manufacturing partner for tafoxiparin in the US, European, CIS and Japanese markets.
In addition, Opocrin will supply manufacturing services during clinical development of tafoxiparin, while the companies will jointly develop the commercial manufacturing of the drug.
Initially, the deal will focus on the clinical supply of tafoxiparin in support of the Phase II and Phase III clinical trial program in obstetrical indications.
Opocrin will also provide services and manufacturing needed to take tafoxiparin through those clinical studies as well as prepare for the commercial supply of the drug in major markets such as US, EU, Japan and CIS.
Opocrin managing director Giulia Falcone said: "The candidate drug addresses important medical needs and has potential to improve delivery which leads to better fetal and maternal health."